Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
LXM-2: Oral GLP-1 Agonist Therapy Formulation of a 3D screen-printed tablet for oral administration of peptides using a GLP-1 receptor agonist in combination with a permeation enhancer as an example - 2024 INP 0153 LXM-2 is an innovative oral formulation of GLP-1 receptor agonists designed to treat type 2 diabetes and obesity
Think of peptide therapy as a wellness layer alongside your heart care, not a substitute for it
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
Philadelphia, PA: Lipincott Williams & Wilkins
US$ 29.40
US$ 28.61
US$ 21.07
US$ 25.70
US$ 26.88
